UroGen Pharma Analyst Ratings
UroGen Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/01/2023 | 149.31% | HC Wainwright & Co. | $23 → $54 | Maintains | Buy |
| 07/31/2023 | -16.9% | Goldman Sachs | $11 → $18 | Maintains | Neutral |
| 06/21/2023 | 6.19% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/15/2023 | 1.57% | Oppenheimer | → $22 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 6.19% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/02/2023 | 6.19% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 04/10/2023 | 6.19% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/16/2023 | 6.19% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/08/2023 | -53.83% | Jefferies | $35 → $10 | Downgrades | Buy → Hold |
| 12/12/2022 | 6.19% | HC Wainwright & Co. | $26 → $23 | Maintains | Buy |
| 04/27/2022 | -7.66% | Berenberg | → $20 | Initiates Coverage On | → Buy |
| 03/22/2022 | -49.22% | Goldman Sachs | $10 → $11 | Maintains | Neutral |
| 01/18/2022 | 56.97% | HC Wainwright & Co. | $50 → $34 | Maintains | Buy |
| 04/27/2021 | 130.84% | HC Wainwright & Co. | $57 → $50 | Maintains | Buy |
| 04/17/2020 | 116.99% | Oppenheimer | $45 → $47 | Maintains | Outperform |
| 04/16/2020 | 163.16% | HC Wainwright & Co. | $53 → $57 | Reiterates | → Buy |
| 04/13/2020 | 144.69% | HC Wainwright & Co. | $75 → $53 | Maintains | Buy |
| 04/06/2020 | 107.76% | Oppenheimer | $47 → $45 | Maintains | Outperform |
| 01/13/2020 | 140.07% | Oppenheimer | $62 → $52 | Maintains | Outperform |
| 11/13/2019 | 80.06% | JP Morgan | $40 → $39 | Maintains | Neutral |
| 05/30/2019 | 89.29% | JP Morgan | → $41 | Initiates Coverage On | → Neutral |
| 05/29/2019 | 130.84% | Goldman Sachs | → $50 | Initiates Coverage On | → Neutral |
| 01/29/2019 | 278.58% | HC Wainwright & Co. | → $82 | Initiates Coverage On | → Buy |
| 11/08/2018 | 255.49% | Jefferies | → $77 | Assumes | → Buy |
| 09/14/2018 | 223.18% | Stifel | → $70 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/01/2023 | 149.31% | HC Wainwright公司 | $23→$54 | 維護 | 買 |
| 07/31/2023 | -16.9% | 高盛 | $11→$18 | 維護 | 中性 |
| 2023年6月21日 | 6.19% | HC Wainwright公司 | →$23 | 重申 | 購買→購買 |
| 2023年05月15日 | 1.57% | 奧本海默 | →$22 | 重申 | 跑贏→跑贏大盤 |
| 2023年05月15日 | 6.19% | HC Wainwright公司 | →$23 | 重申 | 購買→購買 |
| 05/02/2023 | 6.19% | HC Wainwright公司 | →$23 | 重申 | →購買 |
| 04/10/2023 | 6.19% | HC Wainwright公司 | →$23 | 重申 | →購買 |
| 02/16/2023 | 6.19% | HC Wainwright公司 | →$23 | 重申 | →購買 |
| 02/08/2023 | -53.83% | 傑富瑞 | $35→$10 | 評級下調 | 購買→Hold |
| 2022年12月12日 | 6.19% | HC Wainwright公司 | $26→$23 | 維護 | 買 |
| 04/27/2022 | -7.66% | 貝倫伯格 | →$20 | 開始承保 | →購買 |
| 03/22/2022 | -49.22% | 高盛 | $10→$11 | 維護 | 中性 |
| 01/18/2022 | 56.97% | HC Wainwright公司 | $50→$34 | 維護 | 買 |
| 04/27/2021 | 130.84% | HC Wainwright公司 | $57→$50 | 維護 | 買 |
| 04/17/2020 | 116.99% | 奧本海默 | $45→$47 | 維護 | 跑贏大盤 |
| 04/16/2020 | 163.16% | HC Wainwright公司 | $53→$57 | 重申 | →購買 |
| 04/13/2020 | 144.69% | HC Wainwright公司 | $75→$53 | 維護 | 買 |
| 04/06/2020 | 107.76% | 奧本海默 | $47→$45 | 維護 | 跑贏大盤 |
| 2020/01/13 | 140.07% | 奧本海默 | $62→$52 | 維護 | 跑贏大盤 |
| 2019年11月13日 | 80.06% | 摩根大通 | $40→$39 | 維護 | 中性 |
| 2019年05月30日 | 89.29% | 摩根大通 | →$41 | 開始承保 | →中性 |
| 2019年05月29日 | 130.84% | 高盛 | →$50 | 開始承保 | →中性 |
| 2019年01月29日 | 278.58% | HC Wainwright公司 | →$82 | 開始承保 | →購買 |
| 2018/08/11 | 255.49% | 傑富瑞 | →$77 | 假設 | →購買 |
| 2018年09月14日 | 223.18% | Stifel | →$70 | 開始承保 | →購買 |
What is the target price for UroGen Pharma (URGN)?
UroGen Pharma(URGN)的目標價是多少？
The latest price target for UroGen Pharma (NASDAQ: URGN) was reported by HC Wainwright & Co. on August 1, 2023. The analyst firm set a price target for $54.00 expecting URGN to rise to within 12 months (a possible 149.31% upside). 10 analyst firms have reported ratings in the last year.
優羅根製藥(納斯達克：URGN)的最新目標價是由HC Wainwright&Co.於2023年8月1日報道的。這家分析公司將目標價定為54美元，預計URGN將在12個月內上漲至(可能上漲149.31%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for UroGen Pharma (URGN)?
UroGen Pharma(URGN)的最新分析師評級是多少？
The latest analyst rating for UroGen Pharma (NASDAQ: URGN) was provided by HC Wainwright & Co., and UroGen Pharma maintained their buy rating.
優羅根製藥(納斯達克代碼：URGN)的最新分析師評級由HC Wainwright&Co.提供，優羅根製藥維持買入評級。
When is the next analyst rating going to be posted or updated for UroGen Pharma (URGN)?
UroGen Pharma(URGN)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與UroGen Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。UroGen Pharma的上一次評級是在2023年8月1日提交的，所以你應該預計下一次評級將在2024年8月1日左右的某個時候提供。
Is the Analyst Rating UroGen Pharma (URGN) correct?
分析師評級UroGen Pharma(URGN)正確嗎？
While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a maintained with a price target of $23.00 to $54.00. The current price UroGen Pharma (URGN) is trading at is $21.66, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的UroGen Pharma(URGN)評級維持不變，目標價在23.00美元至54.00美元之間。UroGen Pharma(URGN)目前的交易價格為21.66美元，超出了分析師的預測區間。